Mounjaro Dosage Chart in Units: What Each Strength Means for Your Treatment

What 'units' actually means on a Mounjaro dosage chart

Unlike insulin, which is drawn from a vial and measured in international units on a syringe, Mounjaro arrives as a pre-filled, pre-set KwikPen. There is nothing to draw up, no unit markings to read, no dial to set. When people search for a tirzepatide dosage chart in units, they are usually asking one of two things: either how the milligram strengths compare to one another in relative terms, or whether Mounjaro is measured like insulin. The answer to the second question is no, and if you want a full breakdown of how those milligram figures translate in practice, our page on tirzepatide dosage in units explains exactly what the numbers mean and how each pen is measured.

The six strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) are each contained in a separate pen. Moving from one to the next is not a matter of dialling up a number; it means starting a new pen at the next strength. Your prescriber selects that pen based on how you have responded to the previous dose, not on a fixed schedule. The Mounjaro dosage chart is therefore a clinical escalation guide rather than a calibration tool. The NHS medicines information on tirzepatide confirms this structure and is worth reading alongside your Patient Information Leaflet.

Understanding this distinction matters because it shapes how you think about your treatment. The 'units' you see on charts online are milligram doses, not syringe units. That clarity alone removes a common source of confusion for new patients.

The escalation logic: why the chart climbs slowly

The standard Mounjaro schedule moves from 2.5 mg upward in roughly 4-week steps, but the pace is always at the prescriber's discretion. The 2.5 mg pen exists to settle your digestive system, nausea, loose stools and indigestion are most likely during the early weeks, and starting low significantly reduces their severity. Think of it less as a therapeutic dose and more as an introduction. Most people notice appetite changes even at 2.5 mg, but the weight-loss effect builds gradually as the dose rises.

Each step up the tirzepatide dosage chart represents both a higher receptor-level stimulus and a renewed adjustment period. Prescribers typically want to see that you have tolerated the current strength before moving to the next. If side effects are still pronounced at week four, staying at the current dose for longer is clinically reasonable, the chart describes the minimum time at each level, not a rigid countdown. This is why the tirzepatide dosage chart should be read as a floor, not a deadline.

Clinical trial data published in the New England Journal of Medicine (SURMOUNT-1, involving 2,539 adults) showed average body-weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks. Reaching that dose safely depends entirely on how well each preceding step was tolerated, which is why slow and steady titration is built into the licensed schedule, not an optional preference. You can read more about the evidence on the Mounjaro overview page.

Which dose are you actually aiming for?

This is the decision at the centre of most conversations about the Mounjaro dosage chart in units. The licensed maximum is 15 mg, but 15 mg is not automatically the target. Some people achieve their clinical goals at 5 mg or 7.5 mg and stay there. Others need to climb higher. The prescriber's job is to assess your weight response, your side-effect profile and your overall health picture at each review, and to decide whether going further is warranted.

Eligibility for Mounjaro in the UK requires a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. The NICE appraisal of tirzepatide (TA1026) notes that continuing treatment should be reviewed if less than 5% weight loss has been achieved after six months at the highest tolerated dose. That review belongs with your prescriber, the chart cannot make that call for you.

One practical detail that often surprises people: the pen you are currently on stays in the fridge door between uses, but the titration step is a clinical event, not a date in the calendar. Keep a simple note of when you started each strength so your prescriber has the timeline at review. If you are wondering how long a given dose stays active in your system, there is useful background on the pharmacokinetics of the 2.5 mg dose. For questions about a specific strength, the 5 mg dose page covers that step in more detail.

Getting the right dose: what a private clinical review involves

Because Mounjaro is a prescription-only medicine, no dosage chart (in units or milligrams) can replace the clinical assessment that determines which step is right for you. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, not automated software. That review considers your current weight, any conditions you have disclosed, medications that might interact, and your response to any previous treatment.

Transfer patients (people already on Mounjaro who want to continue through our pharmacy) are asked to provide evidence of their current dose so prescribers can confirm the right starting point, rather than defaulting everyone to 2.5 mg. Dose increases require the same clinical sign-off each time. You can read about how to access Mounjaro through a regulated UK pharmacy, and if you would like to explore all available weight-loss treatments, the weight-loss overview covers what is currently licensed and dispensed in the UK.

The dosage chart gives you a map. The prescriber gives you a route that fits your circumstances. Speak to our prescribers if you want a clinical view on where you are in the schedule and what comes next.